Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease
NCT ID: NCT02267434
Last Updated: 2016-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2014-12-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In total 36 patients will be enrolled in 3 independent groups (2 treatment groups, 1 Placebo group), each consisting of 12 patients. The patients will be randomized to either receive 15µg or 75µg AFFITOPE® PD03A formulated with adjuvant or the reference substance without active component (Placebo). Over a study duration of 52 weeks, the study participants receive 4 injections as basic immunization in a 4-weekly interval and 1 boost immunization 36 weeks after the first injection. Male and female patients aged 45 to 70 years can participate in the trial. 2 study sites in Austria (Innsbruck and Vienna) will be involved.
AFF011 is part of a project SYMPATH funded by the European Commission (FP7-HEALTH-2013-INNOVATION-1 project; N° HEALTH-F4-2013-602999).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose AFFITOPE® PD03A + Adjuvant
4 injections of 15µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks
1 boost immunization 36 weeks after first injection
Low dose AFFITOPE® PD03A + Adjuvant
s.c. injection
High dose AFFITOPE® PD03A + Adjuvant
4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks
1 boost immunization 36 weeks after first injection
High dose AFFITOPE® PD03A + Adjuvant
s.c. injection
Adjuvant without active component
4 injections of Placebo once every 4 weeks
1 administration 36 weeks after first injection
Adjuvant without active component
s.c. injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low dose AFFITOPE® PD03A + Adjuvant
s.c. injection
High dose AFFITOPE® PD03A + Adjuvant
s.c. injection
Adjuvant without active component
s.c. injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The result of a DAT-SPECT and MRI examination of the patient's brain has to be consistent with the diagnosis of PD
* Written Informed Consent Form signed and dated by the patient
* Age between 45 and 70
* Female patients of childbearing potential are eligible if they use a medically accepted contraceptive method
* A potential participant treated with conventional PD therapies must be on stable doses for at least 3 months prior to Visit 0 and during the entire trial period and must be a stable responder
* Accepted PD medications include the following: levodopa (alone or in combination with benserazide, carbidopa), Catechol-O-methyltransferase inhibitors (entacapone, tolcapone), amantadine, non-ergot dopamine agonists (pramipexol, ropinirol, rotigotine), monoamine oxidase-B inhibitors (rasagiline, selegiline) and anticholinergic medication
* A potential participant has to be on stable doses of all medications he/she is taking because of consisting illnesses according to medical history (except PD therapies, these will be recorded separately) for at least 30 days prior to Visit 0, if considered relevant by the PI
* Upon PI's opinion, no visual or auditory impairments that would reduce the patients' ability to complete study questionnaires or be unable to receive instructions for these
Exclusion Criteria
* Sexually active women of childbearing potential who are not using a medically accepted birth control method throughout the study
* Participation in another clinical trial within 3 months before Visit 0
* History of questionable compliance to visit schedule; patients not expected to complete the clinical trial
* Presence or history of allergy to components of the vaccine, if considered relevant by the PI
* Contraindication for MRI imaging such as metallic endoprosthesis or stent implantation in the last 6 months or allergy to MRI contrast agent
* Contraindication for DAT-SPECT
* Contraindication for lumbar puncture such as anticoagulation
* Dementia
* History and/or presence of autoimmune disease, if considered relevant by the PI
* Recent (≤3 years since last specific treatment) history of cancer (Exceptions: basal cell carcinoma, intraepithelial cervical neoplasia)
* Active infectious disease (e.g., Hepatitis B, C)
* Presence and/or history of Immunodeficiency (e.g., HIV)
* Significant systemic illness (e.g., chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, other deficiencies), if considered relevant by the PI
* History of significant psychiatric illness such as schizophrenia, bipolar affective disorder or psychotic depression
* Parkinson-like disease secondary to drug therapy side effects (e.g., due to exposure to medications that deplete dopamine \[reserpine, tetrabenazine\] or block dopamine receptors \[neuroleptics, antiemetics\]
* Parkinson-plus syndromes (e.g. MSA, PSP)
* Heredodegenerative disorders
* Alcoholism or substance abuse within the past year (alcohol or drug intoxication)
* Prior and/or current treatment with experimental immunotherapeutics including intravenous immunoglobulin
* Prior and/or current treatment with immunosuppressive drugs
* Change in dose of standard treatments for PD within 3 months prior to Visit 0
* Change in dose of previous and current medications which the patient is taking because of consisting illnesses according medical history (except PD therapies, these will be recorded separately) within the last 30 days prior to Visit 0, if clinically relevant
* Treatment with deep brain stimulation
* Venous status rendering it impossible to place an i.v. access
* L-Dopa related motor complications (response fluctuations and/or dyskinesia)
* Evidence for genetic forms of PD: leucine-rich repeat kinase 2 and Parkin
45 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PROSENEX AmbulatoriumbetriebsGMBH
UNKNOWN
Medical University Innsbruck
OTHER
Forschungszentrum Juelich
OTHER
Affiris AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Werner Poewe, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University Innsbruck, Department of Neurology, Innsbruck 6020, Austria
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University Innsbruck, Department of Neurology
Innsbruck, , Austria
Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an der Confraternität -Privatklinik Josefstadt
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-000568-16
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AFFiRiS 011
Identifier Type: -
Identifier Source: org_study_id